Second Clinical Site for STAR-LLD Ph 1b Trial in Multiple Myeloma opened
Pedro Lichtinger, CEO of Starton, conveyed a positive outlook, expressing confidence by stating, “We are very pleased with the acceleration of our Phase 1b clinical study and with efficacy and tolerability patient outcomes to date. Results like these keep our team laser focused on achieving our important mission to have patients live longer while improving their quality of life, all while driving value for our stakeholders.” Mr. Lichtinger underscored the absence of significant hematologic toxicity and drug-related adverse events, aligning with the findings from preclinical studies conducted during the Investigational New Drug (IND) enabling phase.
Share:
More News
“We are pleased to evaluate the clinical combination of IDE892 with RG6505 in MTAP-deleted RAS-mutant PDAC,” said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. “This collaboration aligns with our broader clinical strategy to evaluate rational combinations with assets in our MTAP-deletion portfolio, and there remains especially high
“In the first reported data from the clinical combinations of our PRMT5 inhibitor vopimetostat and RAS(ON) inhibitors, we saw extremely encouraging early results, with 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieving an objective response, supporting the preclinical data showing synergistic activity of PRMT5 + RAS
“Non-small cell lung cancer is the most prevalent lung disease with more than 8,000 patients in the U.S. diagnosed each year with KRAS G12D-mutations. Receiving Fast Track designation for VS-7375 reinforces both the significant unmet need and the potential of VS-7375 to improve outcomes for patients with KRAS G12D-mutated lung
“KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years,” said John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, Research & Development, Johnson & Johnson. “We believe the proprietary Firelink™ platform will overcome